Search
Eravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalIt was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive
Products: XERAVA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG PER VIALChikungunya virus Senegal strain 37997 capsid protein
go.drugbank.com/drugs/DB21766ApprovedInvestigationalOne of three components of a recombinant Chikungunya virus vaccine called Vimkunya.
Chikungunya virus Senegal strain 37997 envelope protein E2
go.drugbank.com/drugs/DB21768ApprovedInvestigationalOne of three components of a recombinant Chikungunya virus vaccine called Vimkunya.
Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian
Methylphenobarbital
go.drugbank.com/drugs/DB00849ApprovedIt has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.
Isatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigational[L12099,L12102] It is manufactured by Sanofi-Aventis U.S. under the brand name Sarclisa.[L12102] … [L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma.
Hycanthone
go.drugbank.com/drugs/DB14061ExperimentalPotentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.
Piperaquine
go.drugbank.com/drugs/DB13941ApprovedInvestigationalEurartesim was first authorized for market by the European Medicines Agency in October 2011.
Linerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigational[A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). … [A275482, L56120] Linerixibat functions by interrupting the enterohepatic circulation of these bile acids, thereby reducing their systemic concentration.[A275482]
Fidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigational[A190492] Later that year in December, the drug was also approved by the European Medicine Agency.[A190492] In June 2012, fidaxomicin was also granted approval by Health Canada. … [A7445] It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription.